Employees: 03 (2023.0)Legal category: 5485Size: PMECreation date: 2013-05-13 (12 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: SAINT-CIERS-SUR-GIRONDE (33820), Gironde
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
SELARL PHARMACIE CREGUT : revenue, balance sheet and financial ratios
SELARL PHARMACIE CREGUT is a French company
founded 12 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in SAINT-CIERS-SUR-GIRONDE (33820),
this company of category PME
shows in 2025 a net income positive of 84 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELARL PHARMACIE CREGUT (SIREN 793113986)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net income
83 704 €
189 658 €
-9 888 €
104 501 €
93 028 €
95 957 €
93 530 €
104 017 €
109 100 €
85 728 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, SELARL PHARMACIE CREGUT generates positive net income of 84 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2025: 86 k€ -> 84 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
83 704 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 5%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 85%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
5.131%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
85.32%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
160.543
122.579
92.538
70.403
51.979
36.681
23.112
16.107
4.205
5.131
Financial autonomy
35.078
40.518
47.871
54.436
59.249
66.309
72.028
74.904
83.729
85.32
Repayment capacity
None
None
None
None
None
None
None
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
5.132025
2023
2024
2025
Q1: 13.57
Med: 49.47
Q3: 128.28
Excellent
In 2025, the debt ratio of SELARL PHARMACIE CREGUT (5.13) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
Financial autonomy
85.32%2025
2023
2024
2025
Q1: 33.69%
Med: 53.88%
Q3: 72.26%
Excellent+11 pts over 3 years
In 2025, the financial autonomy of SELARL PHARMACIE CREGUT (85.3%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 161.60. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
170.326
169.547
180.294
189.583
156.579
146.613
128.825
127.216
105.359
161.596
Interest coverage
None
None
None
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
161.62025
2023
2024
2025
Q1: 131.48
Med: 182.6
Q3: 258.72
Average+16 pts over 3 years
In 2025, the liquidity ratio of SELARL PHARMACIE CREGUT (161.60) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Positioning of SELARL PHARMACIE CREGUT in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of SELARL PHARMACIE CREGUT is estimated at
1 329 647 €
(range 902 305€ - 2 086 400€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
902k€1329k€2086k€
1 329 647 €Range: 902 305€ - 2 086 400€
NAF 5 année 2025
Valuation method used
Net Income Multiple
83 704 €
×
15.9x
=1 329 648 €
Range: 902 305€ - 2 086 401€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELARL PHARMACIE CREGUT with other companies in the same sector:
Frequently asked questions about SELARL PHARMACIE CREGUT
What is the revenue of SELARL PHARMACIE CREGUT ?
The revenue of SELARL PHARMACIE CREGUT is not publicly disclosed (confidential accounts filed with INPI).
Is SELARL PHARMACIE CREGUT profitable?
Yes, SELARL PHARMACIE CREGUT generated a net profit of 84 k€ in 2025.
Where is the headquarters of SELARL PHARMACIE CREGUT ?
The headquarters of SELARL PHARMACIE CREGUT is located in SAINT-CIERS-SUR-GIRONDE (33820), in the department Gironde.
Where to find the tax return of SELARL PHARMACIE CREGUT ?
The tax return of SELARL PHARMACIE CREGUT is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELARL PHARMACIE CREGUT operate?
SELARL PHARMACIE CREGUT operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart